Investors on Dalal Street seem to draw strength from a strong set of corporate numbers along with firm cues from global peers, indicating a firm start for the benchmark indices even as India reported a record jump in Covid cases. Some volatility cannot be ruled out in today s session on account of the weekly F&O expiry. Furthermore, stock-specific triggers are also likely to sway market moves. At 7.20 am, SGX Nifty was ruling 90 points higher at 14,783. India s second Covid-19 wave turned grimmer as both the fresh case count and daily deaths scaled new peaks in the last 24 hours. India recorded 4.12 lakh new cases, while the death toll neared the 4,000 mark at 3,980.
Tata Steel reported consolidated net profit to Rs 6,644.15 crore in Q4 March 2021 (Q4FY21) as compared with net loss of Rs 1,481.34 crore in Q4 March 2020 (Q4FY20). Total income rose 34.6% to Rs 50,430.36 crore.
Wipro announced a partnership with Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI). This partnership combines Transcell s innovative stem cell technology with the advanced augmented intelligence capabilities of Wipro HOLMES to improve the safety of global vaccine immunization programs.
Shares of Cipla will be in focus. Roche India announced that the Central Drugs Standards Control Organisation (CDSCO) has provided an Emergency Use Authorisation (EUA) for Roche s antibody cocktail (Casirivimab and Imdevimab) in India. This approval was based on the data that have been filed for the EUA in the United States, and the scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) in the European Union.
The Casirivimab-Imdevimab injection is a cocktail of two monoclonal antibodies and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes Covid-19. The monoclonal antibodies are produced by recombinant DNA technology.The
India approves antibody cocktail for emergency use to treat Covid-19
From CNN’s Sarah Dean and Manveena Suri
India has approved Roche/Regeneron’s antibody cocktail for emergency use to treat Covid-19, as essential medical supplies run low in the country amid a devastating second wave of infections.
The country’s Central Drugs Standards Control Organisation (CDSCO) provided an Emergency Use Authorisation (EUA) for Roche’s antibody cocktail in India based on data that has been filed for the EUA in the United States and the scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) in the European Union, Roche India said in a statement on Wednesday.